BriaCell Adds Two Clinical Trial Sites to Accelerate Patient Enrollment PHILADELPHIA, PA and VANCOUVER, British Columbia

Adds Two Clinical Trial Sites to Accelerate Patient Enrollment

PA and VANCOUVER, British Columbia, February 28, 2022- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"

or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast

cancer, announces that it has recruited two additional clinical sites for screening and enrolling advanced breast cancer patients in

the Phase I/IIa combination study of BriaCell's lead candidate, Bria-IMT , with Incyte's checkpoint inhibitor, retifanlimab,

and its immunomodulator, epacadostat. The additional clinical sites include the following: 1) Atlantic Health System, Morristown, New

Jersey, and 2) Tranquil Clinical Research, Webster, Texas.

clinical sites work closely with Cancer Insight, LLC to manage the clinical and regulatory aspects of the Phase I/IIa clinical trial

in advanced breast cancer on behalf of BriaCell. The following clinical sites are now open and actively enrolling patients:

outstanding clinical sites greatly expand our geographical reach allowing more patients to access our innovative therapies as part of

our ongoing study," stated Dr. Bill Williams, BriaCell's President and CEO. "There is an urgent need for well-tolerated

and effective treatments for advanced breast cancer patients, and we look forward to working with the leading oncologists and care providers

at these clinical sites to make these treatments available."

in 1996, Atlantic Health System was formed to provide quality, affordable and accessible care to patients in northern and central New

Jersey. Committed to its mission of building healthier communities, it has grown to a network of over 17,000 members and 4,800 physicians.

Atlantic Health System serves over one million patients annually through 400 sites of care, including seven hospitals, 300 physician

practices, 16 urgent care centers, home care and hospice services, mobile health, telehealth, and collaborative partnerships in education,

research and community health receiving several clinical awards from U.S. News & World Report.

over 30 years of experience, Tranquil Clinical Research, has been providing novel treatments to patients in Webster, Texas. Its focus

has been on excellence in the clinical trial process and bringing trustworthy products to patients. The facility is strategically located

near Texas Medical Center (TMC), Houston, Texas, the world's largest medical complex.

BriaCell Therapeutics Corp.

is an immuno-oncology focused biotechnology company developing targeted and effective approaches for the management of cancer. More information

is available at https://briacell.com/.

press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,

other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements

contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"

"could," "estimate," "expect," "intend," "seek," "may," "might,"

"plan," "potential," "predict," "project," "target," "aim," "should,"

"will," "would," or the negative of these words or other similar expressions, although not all forward-looking

statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent

uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions

as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading

"Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under "Risks

and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities

and Exchange Commission, all of which are available under our profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.

Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty

to update such information except as required under applicable law.

Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts

responsibility for the adequacy or accuracy of this release.

William V. Williams, MD

Director of Public Relations